Skip to main content

Pituitary OnlineFirst articles

23.03.2024

Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades

Acromegaly is a chronic rare disease caused by GH-secreting pituitary adenomas[ 1 ]. Acromegaly is associated with increased morbidity, impaired quality of life and reduced life expectancy, mainly due to cardiovascular disease and cancer [ 2 , 3 ].

verfasst von:
V. Amodru, N. Sahakian, C. Piazzola, R. Appay, T. Graillon, T. Cuny, I. Morange, F. Albarel, M. Vermalle, J. Regis, H. Dufour, T. Brue, F. Castinetti

Open Access 18.03.2024

Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center

Prolactinomas represent the most common cause of hyperprolactinemia and account for 40% of all pituitary adenomas [ 1 ]. Prolactinoma has a prevalence of 60–100 cases/million, and it is more common in women, especially those aged 20 to 50 years [ 2 …]. In women, hyperprolactinemia is a frequent cause of anovulatory cycles and infertility, but fertility can often be restored by treatment with dopamine agonists (DAs) [

verfasst von:
Nunzia Prencipe, Chiara Bona, Daniela Cuboni, Alessandro Maria Berton, Fabio Bioletto, Emanuele Varaldo, Luigi Simone Aversa, Michela Sibilla, Valentina Gasco, Ezio Ghigo, Silvia Grottoli

Open Access 14.03.2024

Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2

During pituitary development, undifferentiated stem cells of the Rathke’s pouch generate all committed cell lineages of the anterior pituitary gland, following downregulation of stem cell transcription factors and upregulation of lineage specific …

verfasst von:
Nèle F. Lenders, Tanya J. Thompson, Jeanie Chui, Julia Low, Warrick J. Inder, Peter E. Earls, Ann I. McCormack

13.03.2024 | Correction

Correction: Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

verfasst von:
Mussa H. Almalki, Moayad A. Alsuraikh, Eyad Almalki, Faisal Aziz, Raya Almazrouei, Khaled M AlDahmani, Fahad Alshahrani, Meshal Alaqeel, Moeber Mahzari, Aishah Ekhzaimy

21.02.2024

Glucose intolerance in acromegaly is driven by low insulin secretion; results from an intravenous glucose tolerance test

Glucose intolerance is a frequent complication of active acromegaly [ 1 – 3 ]. It considerably impacts disease burden and choice of treatment [ 4 , 5 ], whether by itself or by interacting with other comorbidities like hypertrophic cardiomyopathy [ …6

verfasst von:
Laura Georgiana Zaifu, Dan Alexandru Niculescu, Andreea Elena Kremer, Andra Caragheorgheopol, Mariana Sava, Carmen Nicoleta Iordachescu, Roxana Dusceac, Iulia Florentina Burcea, Catalina Poiana

12.02.2024

Elevated risk of recurrence and retreatment for silent pituitary adenomas

Pituitary adenomas are the most common pituitary tumors, and account for nearly 10–15% of all intracranial masses [ 1 , 2 ]. The reported prevalence of these tumors in the United States ranges from 76 to 116 cases per 100,000 people, though imaging …

verfasst von:
Saksham Gupta, Samantha E. Hoffman, Neel H. Mehta, Blake Hauser, Marcelle Altshuler, Joshua D. Bernstock, Timothy R. Smith, Omar Arnaout, Edward R. Laws

12.02.2024

Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Prolactinomas are the most frequent functioning pituitary adenomas and account for approximately half of all pituitary adenomas [ 1 , 2 ]. Dopamine agonists (DAs) are currently the treatment of choice for prolactinoma management, leading to …

verfasst von:
Mussa H. Almalki, Moayad A. Alsuraikh, Eyad Almalki, Faisal Aziz, Raya Almazrouei, Khaled M AlDahmani, Fahad Alshahrani, Meshal Alaqeel, Moeber Mahzari, Aishah Ekhzaimy

Open Access 05.02.2024

Different patient versus provider perspectives on living with Cushing’s disease

Patients with rare diseases face challenges receiving appropriate care. Cushing’s disease (CD), a condition associated with excess endogenous glucocorticoids due to an ACTH-secreting pituitary tumor, is a rare disease, occurring in 0.7 to 2.4 per …

verfasst von:
Amanda Halstrom, I.-Hsin Lin, Andrew Lin, Marc Cohen, Viviane Tabar, Eliza B. Geer

Open Access 31.01.2024

Pituitary hypophysitis in granulomatosis with polyangiitis (GPA): a case series

Granulomatosis with polyangiitis (GPA) rarely involves the pituitary gland. Pituitary involvement has been reported in ~ 1% of all cases of GPA. Most commonly, pituitary swelling and inflammation results in symptoms due to pituitary mass effect …

verfasst von:
Majid Alameri, Abdulla Alnuaimi, Niamh M. Martin, Karim Meeran, Anastasia Gontsarova, Tara D. Barwick, Spencer Ellis, Stephen McAdoo, James Tomlinson, Florian Wernig

25.01.2024

Successful treatment of medically and surgically refractory lymphocytic hypophysitis with fractionated stereotactic radiotherapy: a single-center experience and systematic literature review

Lymphocytic hypophysitis (LH) is a rare autoimmune inflammation of the pituitary gland that usually occurs in childbearing women in the peripartum period, but men and non-childbearing women may also be affected [ 1 ].

verfasst von:
Mehdi Khaleghi, Guilherme Finger, Kyle C. Wu, Vikas Munjal, Luma Ghalib, Peter Kobalka, Dukagjin Blakaj, Khaled Dibs, Ricardo Carrau, Daniel Prevedello

25.01.2024

Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas

Pituitary adenomas (PA) are tumors arising from the adenohypophyseal cells and one of the most common neoplasms of the central nervous system[ 1 ]. They can be classified according to size into microadenomas (< 1.0 cm) and macroadenomas (larger …

verfasst von:
Monique Alvares Barbosa, Eduardo Giardini Rodovalhe Pereira, Paulo José da Mata Pereira, André Accioly Guasti, Felipe Andreiuolo, Leila Chimelli, Leandro Kasuki, Nina Ventura, Monica R. Gadelha

Open Access 19.01.2024

Basal cortisol in relation to metyrapone confirmation in predicting adrenal insufficiency after pituitary surgery

Pituitary surgery is the preferred treatment for pituitary masses in case of mass effect of the tumor on the opticochiasmatic apparatus or in most of the functional adenomas. Post-surgical adrenal insufficiency may occur and is potentially …

verfasst von:
Pieter E. Huisman, Sarah E. Siegelaar, Jantien Hoogmoed, René Post, Shariefa Peters, Moniek Houben, Jacquelien J. Hillebrand, Peter H. Bisschop, Alberto M. Pereira, Eveline Bruinstroop

Open Access 08.01.2024

A medical chart audit to assess endocrinologist perceptions of the burden of endogenous Cushing’s syndrome

Endogenous Cushing’s syndrome (CS) is a rare, debilitating disorder caused by chronic overproduction of cortisol [ 1 – 3 ]. CS has an estimated incidence of 0.7 to 2.4 cases per million per year, with a majority of cases (~ 70%) occurring in women …

verfasst von:
Gabrielle Page-Wilson, Bhagyashree Oak, Abigail Silber, James Meyer, Matthew O’Hara, Eliza B. Geer

06.01.2024

Current status of artificial intelligence technologies in pituitary adenoma surgery: a scoping review

Pituitary adenoma surgery requires high precision and accuracy to avoid injury to adjacent neurovascular structures. [ 1 ] In patients requiring pituitary adenoma surgery, risk stratification for outcomes prediction is often complex due to the …

verfasst von:
Seyed Farzad Maroufi, Yücel Doğruel, Ahmad Pour-Rashidi, Gurkirat S. Kohli, Colson Tomberlin Parker, Tatsuya Uchida, Mohamed Z. Asfour, Clara Martin, Mariagrazia Nizzola, Alessandro De Bonis, Mamdouh Tawfik-Helika, Amin Tavallai, Aaron A. Cohen-Gadol, Paolo Palmisciano

03.01.2024

Prediction of adrenal insufficiency after pituitary surgery: a retrospective study using beckman access cortisol assay

Pituitary adenomas are among the most common intracranial tumors, accounting approximately for 10–15% of cases [ 1 , 2 ]. Although generally benign and slow-growing tumors, pituitary adenomas can cause symptoms due to their hormonal activity and/or …

verfasst von:
Maria Francesca Birtolo, Emma Giannini, Simone Antonini, Elisabetta Lavezzi, Giovanni Lasio, Giorgio Da Rin, Gherardo Mazziotti, Andrea G. Lania

30.12.2023

Acromegaly increases depressive symptoms and reduces quality of life of cohabitants

Acromegaly is caused by excessive secretion of growth hormone (GH) mostly by pituitary adenoma. It is associated with substantial morbidity and mortality [ 1 ]. Since the diagnosis can take several years, treatment is oftenly delayed [ 2 ].

verfasst von:
Serhat Uysal, Cem Sulu, Zehra Kara, Ilker Ihtiyaroglu, Irem Ozkal, Serdar Sahin, Sabriye Sibel Taze, Mehmet Murat Kirpinar, Senol Turan, Pinar Kadioglu

15.10.2019

Aggressive prolactinomas: how to manage?

Prolactinomas are the most common pituitary tumor representing around 50% of all pituitary tumors. Typical prolactinomas present as microadenomas diagnosed in women of reproductive age. A dopamine agonist (DA) is the first line treatment and …

verfasst von:
Hélène Lasolle, Mirela Diana Ilie, Gérald Raverot

25.09.2019

Dopamine agonists in prolactinomas: when to withdraw?

Dopamine agonists (DAs) are well recognized as the first-line therapy for prolactinomas due to their efficacy in achieving tumoral shrinkage and normoprolactinemia. However, it remains to be established the best timing to withdraw DAs and in which …

verfasst von:
Pedro Souteiro, Sandra Belo, Davide Carvalho